Biotechnology

XTL BioPharma

XTL BioPharma released FY2025 Q2 earnings on December 30 (EST), actual revenue USD 258.5K, actual EPS USD -0.312

XTL BioPharma released FY2025 Semi-Annual Earnings on December 30 (EST), actual revenue USD 517K, actual EPS USD -0.624

XTL BioPharma released FY2025 Q1 earnings on December 30 (EST), actual revenue USD 258.5K, actual EPS USD -0.312

XTL BioPharma released FY2024 Q4 earnings on April 30 (EST), actual revenue USD 405 K, actual EPS USD -0.0909

XTL BioPharma released FY2024 annual earnings on April 30 (EST), actual revenue USD 451 K, actual EPS USD -0.2999

XTL Biopharma Reports $1.03M Net Loss in Fiscal Year 2024

XTL BioPharma released FY2024 Q3 earnings on December 30 (EST) with actual revenue of 46 K USD and EPS of -0.1333 USD

XTL BioPharma released FY2024 9 Months Earnings on December 30 (EST), with actual revenue of 46K USD and EPS of -0.1844 USD

XTL BioPharma released FY2024 Semi-Annual Earnings on December 30 (EST) with actual revenue of 0 USD and EPS of -0.0401 USD

XTL BioPharma released FY2024 Q2 earnings on December 30 (EST) with actual revenue of 0 USD and EPS of -0.1401 USD

TMD Energy

Intelligent Bio Solutions

VerifyMe

Momentus

Lianhe Sowell

Uni-Fuels

Datavault AI

T-REX 2X Long UPXI Daily Target ETF

RISING DRAGON ACQUISITION CORP COM USD0.0001 15/11/2028 (SUBS/RT)

Passage Bio

Adma Biologics

Kiniksa Pharmaceuticals

Stoke Therapeutics

Rigel Pharma

OpGen

Vertex Pharma

Regeneron Pharma

Alnylam Pharma

Argenx

Beigene

Style Score

Growth Score

Revenue YoY

Net Profit YoY

Value Score

P/B Ratio

Dividend Ratio

Size Score

Market Cap Score

Market Cap

Revenue Score

Revenue

Multi Score

Profit Score

Profit Margin

Gross Margin

Total Assets YoY

Net Assets YoY

Cash Score

Cash Flow Margin

OCF YoY

Operating Score

Turnover

Debt Score

Gearing Ratio

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap

XTL BioPharma(XTLB.US)